

CANC 440 CANCER BIOLOGY & THERAPEUTICS**WINTER TERM 2019**

CO-ORDINATOR:	Susan PC COLE (spc.cole@queensu.ca)
TA:	Ivan SHAPOVALOV
ADMINISTRATOR:	Kevin KELL (kevin.kell@queensu.ca)
TIME:	MONDAYS 2:30 - 5:30 PM
LOCATION:	<u>RICHARDSON LABs</u> Room 101

GENERAL COURSE SCHEDULE & FORMAT:

WEEK 1: this session will begin with an orientation by the Course Coordinator and the TA. Orientation will be followed by two introductory 50 min lectures: Cancer Biology and Pathology, and Clinical and Experimental Cancer Therapeutics.

WEEKS 2-11: each class begins with all students (except the students presenting that day) handing in 2 written questions on at least 2 of the papers assigned the week before by the Session Leader. This is followed by student presentations and group discussion (max time ~ 1.5 hrs). Session Leaders add value, corrections, etc. as appropriate. Presentations will be graded by the Session Leader and the TA. Students will also complete 5 assessments of their peers over the 11 weeks of presentations; these will be managed and graded by the TA. After a short break (~15 min), the next Session Leader will present a 50 min Lecture providing background on the topic to be covered by student presentations the following week.

WEEK 12: the first 2 hr will be the final student presentations with the remaining time set aside for students to complete USAT forms under the supervision of the DSC.

Students will be assigned an **Essay Topic** by a Session Leader early in the term (by the end of **WEEK 2**), and are encouraged to meet as soon as possible with their Essay Supervisor to discuss approaches to their Essay. Students are also asked to submit a summary Abstract during **WEEK 7** (and **Essays** will be **due WEEK 10**) to their Essay Supervisor for feedback. All abstracts and essays must be submitted through **Turnitin** on the course website through **OnQ** so they can be evaluated for originality. Grading will be by the Session Leader and the TA.

EVALUATION:

Oral Presentations (2)	2 x 25%
Peer Assessments (5)	5%
Essay Abstract	2% (<i>bonus</i>)
Essay	35%
Participation (includes quality of written questions submitted at beginning of each session, and class participation; attendance)	10%

ABSTRACT and ESSAY:

- **Topic Assignment Date:** *WEEK 2* – 14 - 18 January 2019
- **Abstract Due Date:** *WEEK 7* - 28 February (*latest Thurs 4:00 PM*)
- **Essay Due Date:** *WEEK 10* - 21 March 2019 (*latest Thurs 4:00 PM*)

Faculty	Email	Phone	Faculty	Email	Phone
Dr BERMAN	bermand@queensu.ca	33022	Dr IZARD	jason.izard@kingstonhsc.ca	548-2493
Dr COLE	spc.cole@queensu.ca	32636	Dr MULLIGAN	mulligal@queensu.ca	77475
Dr DAVEY	scott.davey@queensu.ca	36923	Dr RAUH	rauhm@queensu.ca	32818
Dr FEILOTTER	hf4@queensu.ca	32932	Dr ROSSITER	John.rossiter@kingstonhsc.ca	36306
Dr HURLBUT	David.Hurlburt@kingstonhsc.ca	549-6666 x6035	Dr YANG	yangx@queensu.ca	75998

Week	Date <i>Monday</i>	2:30 – 4:30		4:30 – 5:30	
		Session Leader	Student Presentation Topic	Session Leader	Lecture Topic
1	Jan 7	Dr COLE & IVAN Shapovalov 2:30-3:30	<i>none</i>	Dr YANG (Path) 3:30-4:30 ----- Dr COLE (Path) 4:30-5:30	Intro to Cancer Biol & Pathol ----- Intro to Clin & Exp Cancer Therapeutics
**ESSAY TOPICS Due to Ivan Jan 14-18					
2	Jan 14	Dr COLE	Cancer Therapeutics (4)	Dr COLE (Path)	Kidney Cancer
3	Jan 21	Dr COLE	Kidney Cancer (4)	Dr RAUH (Path)	Leukemias & Lymphomas
4	Jan 28	Dr RAUH	Leukemias & Lymphomas (5)	Dr HURLBUT (Path)	Colorectal Cancer
5	Feb 4	Dr HURLBUT	Colorectal Cancer (5)	Dr ROSSITER (Path)	CNS Tumours
6	Feb 11	Dr ROSSITER	CNS Tumours (4)	Dr MULLIGAN (Path)	Pediatric Tumours (non-CNS)
READING WEEK					
7	Feb 25	Dr MULLIGAN	Pediatric Tumours (4)	Dr BERMAN (Path)	Bladder Cancer
**ESSAY ABSTRACT Due Feb 28th					
8	Mar 4	Dr BERMAN	Bladder Cancer (4)	Dr YANG (Path)	Breast Cancer
9	Mar 11	Dr YANG	Breast Cancer (3)	Dr IZARD (Urol)	Prostate Cancer
10	Mar 18	Dr IZARD	Prostate Cancer (4)	Dr YANG (Path)	Gynecological Cancers
**ESSAY Due Mar 21st					
11	Mar 25	Dr YANG	Gynecological Cancers (3)	Drs DAVEY & FEILOTTER (Path)	Lung Cancer
12	Apr 1	Drs DAVEY & FEILOTTER	Lung Cancer (4)	DSC	USAT Evaluations